Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of R-GEMOX plus enzastaurin in relapsed diffuse large B-cell lymphoma
2006-001985-17Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of enzastaurin, rituximab, gemcitabine and oxaliplatin in diffuse large B-cell lymphoma (DLBCL) and transformed B-cell lymphoma, sponsored by Eli Lilly and Company. Primary endpoints: Progression-free survival at 1 year and Overall progression-free survival. Started Sep 2006; status: completed.
02
Drugs
enzastaurinrituximabgemcitabineoxaliplatin
03
Conditions
diffuse large B-cell lymphoma (DLBCL)transformed B-cell lymphoma
Beyond the preview
Go deeper on 2006-001985-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001985-17.